Adelaide

Everything is set for the eighth edition of the Ernesto Illy International Coffee Award, And the expert jury who will decide the winner has been confirmed

Retrieved on: 
Monday, November 6, 2023
Sale, Cerrado, Coffee, ICON, Human, Illy, Publication, B Corporation (certification), Multimedia, Adelaide, Trustmark (benefits company), Restaurant, Earl of Derby, Art, Culture, Welt am Sonntag, Michelin, Beauty, Collection, Memory, Capital

TRIESTE, Italy, Nov. 6, 2023 /PRNewswire/ -- illycaffè has unveiled the jury responsible for determining the recipient of the "Best of the Best" award at the Ernesto Illy International Coffee Award 2023. These judges will convene on November 16th in New York to assess the coffees meticulously chosen by illycaffè's quality labs. Throughout the year, these labs have scrutinized samples from the 2022/2023 harvest and selected the finest lots and producers, focusing on the company's quality and sustainability standards.

Key Points: 
  • These judges will convene on November 16th in New York to assess the coffees meticulously chosen by illycaffè's quality labs.
  • This prestigious accolade, named in memory of Ernesto Illy, the son of the company's founder, commemorates more than three decades of productive collaboration with coffee producers.
  • The international panel consists of three seasoned tasters, three renowned international chefs, and three accomplished journalists.
  • In 2021, Rhône Capital became a minority shareholder of illycaffè with the aim of contributing to the company's international growth plans.

10x Genomics Surpasses 100 Xenium Analyzer Shipments

Retrieved on: 
Tuesday, August 29, 2023
Tissue, Adelaide, University, FISH, Cancer Institute, Rosenbergia xenium, Genomics, Defence Research and Development Laboratory, Bay Adelaide Centre, 10x Genomics, Research, Research fellow, Genetic distance, RNA, Multiple sclerosis, Cell, H&E, Associate, IHC, Chemistry, Colorectal cancer, B cell, Professor, Data analysis, Melanoma, Icahn Genomics Institute, Biology, Basal-cell carcinoma, Growth, SNV, Health, Environment, Rest, MD Anderson Cancer Center, Gene, Disease, Medical imaging, Vaccine

PLEASANTON, Calif., Aug. 29, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that it has shipped more than 100 Xenium Analyzer instruments in the eight months since the platform's launch. The milestone reflects strong customer demand for the Xenium platform, which is increasingly recognized as the best performing system for in situ analysis.

Key Points: 
  • Rapid growth and adoption of Xenium Analyzer demonstrates strength of company's innovation engine, broad commercial reach and operational scale
    PLEASANTON, Calif., Aug. 29, 2023 /PRNewswire/ -- 10x Genomics , Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that it has shipped more than 100 Xenium Analyzer instruments in the eight months since the platform's launch.
  • I firmly believe Xenium has the potential to be one of the most transformative technologies in our industry in decades."
  • With the vast majority of the first 100 Xenium shipments already installed, researchers are using the system to successfully analyze a variety of tissues and sample types, including fresh frozen, FFPE and tissue microarrays, and reveal new insights into health and disease.
  • Also in 2024, 10x Genomics expects to launch an in-line protein assay to combine with the RNA assays on the exact same tissue section.

She's some saucy! Fat Bastard Burrito is opening in St. John's, Newfoundland July 21

Retrieved on: 
Monday, July 10, 2023
Adelaide, Pedestrian, SAT, Sun, GTFO, Protein, Community, Personality, Saint John, Pedestrian malls in the United States, Mouth, Fast food

Introducing Fat Bastard Burrito – the Ontario-born burrito, quesadilla and taco chain that keeps it fun and fresh.

Key Points: 
  • Introducing Fat Bastard Burrito – the Ontario-born burrito, quesadilla and taco chain that keeps it fun and fresh.
  • To celebrate the opening, Fat Bastard Burrito will be giving out limited-edition T-shirts to the first 100 customers!
  • Fat Bastard Burrito is proud to open in St. John's as the city is home of the beloved Mary Brown's Chicken, whose parent company, MBI Brands Inc., acquired Fat Bastard Burrito last summer.
  • "We look forward to introducing Fat Bastard Burrito to the St. John's Community, where we have a strong community of Mary Brown's Chicken fans.

DTEX Partners with Defence Trailblazer to Accelerate Australia’s insider Risk Capability

Retrieved on: 
Wednesday, July 5, 2023
Other Manufacturing, Data Management, Department Stores, Technology, Manufacturing, Retail, Public Relations, Investor Relations, Utilities, Finance, Communications, Consulting, Security, Banking, Accounting, Energy, Professional Services, Software, Networks, Internet, Supply Chain Management, Workforce, Defense, Trailblazer, Partnership, Adelaide, University, UNSW, Australian Security Intelligence Organisation, Risk management, Northrop, Grumman, Intercept, Saab, Risk, ASIO, Raytheon Technologies, Government, Data science, Thales of Miletus, Leidos

DTEX Systems, the global leader in insider risk management, today announced it will play a critical role in uplifting Australia’s defenses against insider threats under a new partnership with the Defence Trailblazer program.

Key Points: 
  • DTEX Systems, the global leader in insider risk management, today announced it will play a critical role in uplifting Australia’s defenses against insider threats under a new partnership with the Defence Trailblazer program.
  • DTEX is one of 35 industry partners to join the $240 million dollar program, which aims to accelerate Australia’s defense innovation and workforce development.
  • DTEX Systems is a cybersecurity company focused on preventing insider risks from becoming insider threats.
  • Under the Defence Trailblazer program, DTEX will support workforce development through an internship program focused on addressing the skills needed to detect, deter, and disrupt insider risks.

Glyscend Therapeutics Announces Positive Topline Phase 2a Clinical Results and Progress with GLY-200, a First-in-Class Treatment for Type 2 Diabetes and Obesity

Retrieved on: 
Wednesday, May 31, 2023
Health, Diabetes, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Exercise, Royal Adelaide Hospital, Parameter, Insulin, Obesity, Adelaide, University, Diet, MBBS, Endocrine system, Type 2 diabetes, Glucose, Novel, Duodenum, PYY, Appetite, Doctor of Philosophy, Phase 1, MD, Patient, Physician, American Diabetes Association, Metformin, Bariatric surgery, Therapy, T2D, Treatment, Safety, Disease, Human, Pharmaceutical industry, Medical device, Dietary supplement, Medicine

T2D and obesity are worldwide endemics with millions of people in need of more effective ways to manage their disease.

Key Points: 
  • T2D and obesity are worldwide endemics with millions of people in need of more effective ways to manage their disease.
  • “Type 2 diabetes and obesity are extremely common chronic diseases where the outcome of most therapeutic options is suboptimal.
  • “These Phase 2a data provide clinical evidence that duodenal exclusion may be possible with a non-invasive, orally administered, pharmaceutical treatment.
  • He will discuss therapeutic targets in the gut for the treatment of T2D and obesity.

Gencove Appoints Alex Dickinson to its Board of Directors

Retrieved on: 
Tuesday, March 21, 2023
Columbia University, DNA, Adelaide, University, Cisco, Genotyping, Infection, Cancer, Electrical engineering, MBA, Genomics, Doctor of Philosophy, Whole genome sequencing, Cloud computing, Patient, Medicine, Luxtera, Electricity, Genome, Management, Illumina

New York, March 21, 2023 (GLOBE NEWSWIRE) -- Gencove, pioneer of low-pass whole genome sequencing and analysis software, is pleased to announce the appointment of Dr. Alex Dickinson to its Board of Directors.

Key Points: 
  • New York, March 21, 2023 (GLOBE NEWSWIRE) -- Gencove, pioneer of low-pass whole genome sequencing and analysis software, is pleased to announce the appointment of Dr. Alex Dickinson to its Board of Directors.
  • He joins Joseph Pickrell and Tomaz Berisa, co-founders of Gencove, Sara Eshelman of Spero Ventures, and Larry Page of Lewis & Clark AgriFood on the Board.
  • “I’m very pleased to join the Gencove Board of Directors,” said Alex.
  • “This addition to the board signals our investment in expanding the commercial reach and maturity of Gencove.

The 31st Annual Masters of Pediatric Dermatology Symposium Reveals New Faces Alongside An Updated Agenda This Coming February 2023

Retrieved on: 
Friday, January 20, 2023
Janus, Infection, Debate, Advisory board, Atopic dermatitis, Catalog, Student, Education, Pediatrics (journal), Face, DO, MS, The Croods: A New Age, Adelaide, Psoriasis, Health, Symposia, Faculty, Pediatrics, Partnership, Mercedes, Patient, Adolescence, American Academy, SGD, Dermatology, SOC, Doctor of Philosophy, Alopecia areata, Janus kinase inhibitor, Skin, Medicine, Pharmaceutical industry, Telehealth, MD

It has also partnered with the American Academy of Pediatrics' local chapters on various educational programs in support of advancing pediatric dermatology education.

Key Points: 
  • It has also partnered with the American Academy of Pediatrics' local chapters on various educational programs in support of advancing pediatric dermatology education.
  • This February, MOPD once again features a variety of pertinent sessions designed to provide the latest information to practicing professionals.
  • Led by world-renowned medical, aesthetic, and pediatric dermatology experts, LiVDerm empowers providers to educate, collaborate, and engage.
  • With a multipronged approach to mastering the myriad of subspecialties within the field, LiVDerm provides innovative and integrated education across the dermatology spectrum.

Global Glycomic Therapeutics Market Forecast to 2028 - Wide Applications of Glycomics in Therapeutics Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 13, 2022
Health, General Health, Therapy, Mode, Network, Development, Alzheimer's disease, Drug discovery, Glycomics, EPO, Patient, Thrombosis, Cancer, Developing country, Anemia, Research, Traumatic brain injury, Erythropoietin, TBI, University of Alberta, Quality of life, Cataract, COVID-19, Quantum Leap, Glycan, University, Adelaide, Merck, Discovery, Trastuzumab, Pharmaceutical industry, Vaccine

The "Glycomic Therapeutics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Class, Structures, Indications, and Mode of Action" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Glycomic Therapeutics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Class, Structures, Indications, and Mode of Action" report has been added to ResearchAndMarkets.com's offering.
  • The global glycomic therapeutics market is expected to grow from US$ 99,021.46 million in 2021 to US$ 257,578.79 million in 2028; it is estimated to grow with a CAGR of 15.8% from 2022 to 2028.
  • Glycan-based therapeutics have wide applications in the pharmaceutical industry; the products are available in different structures & forms and developed as per the application.
  • The glycoprotein is a type of glycan that can be used to deliver drugs, toxins, or radioactive substances directly to cancer cells.

Glycomics Global Market Report 2022: Increased Glycomics Research and Expanding R&D Investments Driving Sector - ResearchAndMarkets.com

Retrieved on: 
Monday, September 5, 2022
Health, Biotechnology, Enzyme, COVID-19, University, National Health, Medical Research Council, Cancer, Research, NHMRC, Adelaide, Investment, Glycosylation, Geography, National Health and Medical Research Council, Biotechnology, CAGR, Institute, Drug discovery, Drug development, Fine chemical, Pharmaceutical industry, Medical device, Glycomics

The report highlights trends prevailing in the market and factors driving the glycomics market.

Key Points: 
  • The report highlights trends prevailing in the market and factors driving the glycomics market.
  • The glycomics market is being driven by increased glycomics research, a rise in R&D investments, and the use of glycomics to treat various diseases, leading to the development of new treatment processes.
  • Additionally, the new tools in glycomics research are likely to emerge as a significant future trend in the market during the forecast period.
  • Therefore, the use in drug development for diseases worldwide is acting as a key factor driving the glycomics market.

IBI Group Announces FY2022 Annual Results, Steadfast Resilience Albeit Market Challenges

Retrieved on: 
Thursday, June 30, 2022
Review, Life, Heart, CEO, Quarantine, Hong Kong Stock Exchange, Adelaide, COVID-19, Adelaide Chamber Singers, Built environment, Growth, Company, Income, IBI, Shinkansen, The Group, Investment, Environment, Board, Group, BSL, Property management, Film

During the year under review, the Group recorded an income of approximately HK$405.9 million (FY2021: HK$556.7 million).

Key Points: 
  • During the year under review, the Group recorded an income of approximately HK$405.9 million (FY2021: HK$556.7 million).
  • The Group maintained a strong financial position with cash and cash equivalents of approximately HK$141.6 million (FY2021: HK$87.1 million) and no bank borrowings as at 31 March 2022.
  • Mr. Neil Howard, Chairman and CEO of IBI, said, "Amid unprecedented challenges created by COVID-19 pandemic, we have remained steadfast and resilient in driving our growth and investment strategies.
  • About IBI Group Holdings Limited (stock code: 1547)
    IBI Group Holdings Limited is a publicly listed holding company on the Hong Kong Stock Exchange, focused on investments in the Built Environment.